Search

Your search keyword '"Kester, Lennart A."' showing total 277 results
Start Over Author "Kester, Lennart A."
277 results on '"Kester, Lennart A."'

2. Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)

Author

Aronson, S. Lot, Walker, Cédric, Thijssen, Bram, van de Vijver, Koen K., Horlings, Hugo M., Sanders, Joyce, Alkemade, Maartje, Koole, Simone N., Lopez-Yurda, Marta, Lok, Christianne A. R., Rottenberg, Sven, van Rheenen, Jacco, Sonke, Gabe S., van Driel, Willemien J., Kester, Lennart A., and Hahn, Kerstin

Published
2024
Full Text
View/download PDF

6. Comparison of clinical selection-based genetic testing with phenotype-agnostic extensive germline sequencing to diagnose genetic predisposition in children with cancer: a prospective diagnostic study

Author

Bakhuizen, Jette J, van Dijk, Freerk, Koudijs, Marco J, Bladergroen, Reno S, Bon, Sebastian B B, Hopman, Saskia M J, Kester, Lennart A, Kranendonk, Mariëtte E G, Loeffen, Jan L C, Smetsers, Stephanie E, Sonneveld, Edwin, Tachdjian, Melissa, de Vos-Kerkhof, Evelien, Goudie, Catherine, Merks, Johannes H M, Kuiper, Roland P, and Jongmans, Marjolijn C J

Published
2024
Full Text
View/download PDF

7. Spindle Cell Lesions with Oncogenic EGFR Kinase Domain Aberrations: Expanding the Spectrum of Protein Kinase–Related Mesenchymal Tumors

Author

Vallese, Silvia, Barresi, Sabina, Hiemcke-Jiwa, Laura, Patrizi, Sara, Kester, Lennart, Giovannoni, Isabella, Cardoni, Antonello, Pedace, Lucia, Nardini, Claudia, Tancredi, Chantal, Desideri, Martina, von Deimling, Andreas, Mura, Rosa M., Piga, Michela, Errico, Maria E., Stracuzzi, Alessandra, Alaggio, Rita, Miele, Evelina, and Flucke, Uta

Published
2024
Full Text
View/download PDF

8. Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial

Author

Linn, Sabine C., Soesan, Marcel, Oosterkamp, Rianne M., Jeurissen, Frank, Weijl, Nir, Imholz, Alex L.T., Portielje, Johanneke E.A., Beelen, Karin J., Bos, Monique E.M.M., van Bochove, Aart, de Klerk, Gerty, Vrijaldenhoven, Suzan, van der Velden, Annette, de Graaf, Hiltje, Smeets, Marielle, Terwogt, Jetske Meerum, Schrama, Jolanda, Kuijer, Philomeen, Wilmink, Hanneke, Hoekstra, Ronald, Kroep, Judith, Pruijt, Hans F.M., van Gerven, Leander, Vos, Allert H., Erdkamp, Frans, van Leeuwen-Breuk, Willemien G., de Graeff, Alexander, Opdam, Mark, van Rossum, Annelot G.J., Hoogstraat, Marlous, Bounova, Gergana, Horlings, Hugo M., van Werkhoven, Erik, Mandjes, Ingrid A.M., van Leeuwen – Stok, A. Elise, Canisius, Sander, van Tinteren, Harm, Bakker, Sandra, Wesseling, Jelle, Kester, Lennart, van Rheenen, Jacco, Rutgers, Emiel J., de Menezes, Renee X., Wessels, Lodewyk F.A., Kok, Marleen, and Oosterkamp, Hendrika M.

Published
2024
Full Text
View/download PDF

9. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Author

Kroeze, Emma, Iaccarino, Ingram, Kleisman, Michelle M., Mondal, Mayukh, Beder, Thomas, Khouja, Mouhamad, Höppner, Marc P., Scheijde-Vermeulen, Marijn A., Kester, Lennart A., Brüggemann, Monika, Baldus, Claudia D., Cario, Gunnar, Bladergroen, Reno S., Garnier, Nathalie, Attarbaschi, Andishe, Verdu-Amorós, Jaime, Sutton, Rosemary, Macintyre, Elizabeth, Scholten, Kenneth, Arias Padilla, Laura, Burkhardt, Birgit, Beishuizen, Auke, den Boer, Monique L., Kuiper, Roland P., Loeffen, Jan L. C., Boer, Judith M., and Klapper, Wolfram

Published
2024
Full Text
View/download PDF

12. Genomic characterization of DICER1-associated neoplasms uncovers molecular classes

Author

Kommoss, Felix K. F., Chong, Anne-Sophie, Chong, Anne-Laure, Pfaff, Elke, Jones, David T. W., Hiemcke-Jiwa, Laura S., Kester, Lennart A., Flucke, Uta, Gessler, Manfred, Schrimpf, Daniel, Sahm, Felix, Clarke, Blaise A., Stewart, Colin J. R., Wang, Yemin, Gilks, C. Blake, Kommoss, Friedrich, Huntsman, David G., Schüller, Ulrich, Koelsche, Christian, Glenn McCluggage, W., von Deimling, Andreas, and Foulkes, William D.

Published
2023
Full Text
View/download PDF

15. NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: A high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker

Author

Pathologie Moleculair, Pathologie Pathologen staf, PMC Medisch specialisten, Genetica, Cancer, Kroeze, Emma, Kleisman, Michelle M., Kester, Lennart A., Scheijde-Vermeulen, Marijn A., Sonneveld, Edwin, Buijs-Gladdines, Jessica G.C., Hagleitner, Melanie M., Meyer-Wentrup, Friederike A.G., Veening, Margreet A., Beishuizen, Auke, Meijerink, Jules P.P., Loeffen, Jan L.C., Kuiper, Roland P., Pathologie Moleculair, Pathologie Pathologen staf, PMC Medisch specialisten, Genetica, Cancer, Kroeze, Emma, Kleisman, Michelle M., Kester, Lennart A., Scheijde-Vermeulen, Marijn A., Sonneveld, Edwin, Buijs-Gladdines, Jessica G.C., Hagleitner, Melanie M., Meyer-Wentrup, Friederike A.G., Veening, Margreet A., Beishuizen, Auke, Meijerink, Jules P.P., Loeffen, Jan L.C., and Kuiper, Roland P.

Published
2024

16. Small cell osteosarcoma versus fusion-driven round cell sarcomas of bone: retrospective clinical, radiological, pathological, and (epi)genetic comparison with clinical implications

Author

Pathologie patiënten zorg, Pathologie Groep Van Diest, Cancer, Onderzoek Beeld, MS Radiologie, Hiemcke-Jiwa, Laura S., Sumathi, Vaiyapuri P., Baumhoer, Daniel, Smetsers, Stephanie E., Haveman, Lianne M., van Noesel, Max M., van Langevelde, Kirsten, Cleven, Arjen H.G., van de Sande, Michiel A.J., ter Horst, Simone A.J., Kester, Lennart A., Flucke, Uta, Pathologie patiënten zorg, Pathologie Groep Van Diest, Cancer, Onderzoek Beeld, MS Radiologie, Hiemcke-Jiwa, Laura S., Sumathi, Vaiyapuri P., Baumhoer, Daniel, Smetsers, Stephanie E., Haveman, Lianne M., van Noesel, Max M., van Langevelde, Kirsten, Cleven, Arjen H.G., van de Sande, Michiel A.J., ter Horst, Simone A.J., Kester, Lennart A., and Flucke, Uta

Published
2024

17. Molecular analysis of cancer genomes in children with Lynch syndrome: Exploring causal associations

Author

Genetica, Genetica Oper.Mang. Clinical Genetics, Cancer, Pathologie patiënten zorg, Pathologie Groep Van Diest, Genetica Klinische Genetica, Child Health, Weijers, Dilys D., Hirsch, Steffen, Bakhuizen, Jette J., van Engelen, Nienke, Kester, Lennart A., Kranendonk, Mariëtte E.G., Hiemcke-Jiwa, Laura S., de Vos-Kerkhof, Evelien, Loeffen, Jan L.C., Autry, Robert J., Pajtler, Kristian W., Jäger, Natalie, Jongmans, Marjolijn C.J., Kuiper, Roland P., Genetica, Genetica Oper.Mang. Clinical Genetics, Cancer, Pathologie patiënten zorg, Pathologie Groep Van Diest, Genetica Klinische Genetica, Child Health, Weijers, Dilys D., Hirsch, Steffen, Bakhuizen, Jette J., van Engelen, Nienke, Kester, Lennart A., Kranendonk, Mariëtte E.G., Hiemcke-Jiwa, Laura S., de Vos-Kerkhof, Evelien, Loeffen, Jan L.C., Autry, Robert J., Pajtler, Kristian W., Jäger, Natalie, Jongmans, Marjolijn C.J., and Kuiper, Roland P.

Published
2024

18. Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement

Author

Onderzoek Beeld, Green, Darrell, van Ewijk, Roelof, Tirtei, Elisa, Andreou, Dimosthenis, Baecklund, Fredrik, Baumhoer, Daniel, Bielack, Stefan S., Botchu, Rajesh, Boye, Kjetil, Brennan, Bernadette, Capra, Michael, Cottone, Lucia, Dirksen, Uta, Fagioli, Franca, Fernandez, Natalia, Flanagan, Adrienne M., Gambarotti, Marco, Gaspar, Nathalie, Gelderblom, Hans, Gerrand, Craig, Gomez-Mascard, Anne, Hardes, Jendrik, Hecker-Nolting, Stefanie, Kabickova, Edita, Kager, Leo, Kanerva, Jukka, Kester, Lennart A., Kuijjer, Marieke L., Laurence, Valérie, Lervat, Cyril, Marchais, Antonin, Marec-Berard, Perrine, Mendes, Cristina, Merks, Johannes H.M., Ory, Benjamin, Palmerini, Emanuela, Pantziarka, Pan, Papakonstantinou, Evgenia, Piperno-Neumann, Sophie, Raciborska, Anna, Roundhill, Elizabeth A., Rutkauskaite, Vilma, Safwat, Akmal, Scotlandi, Katia, Staals, Eric L., Strauss, Sandra J., Surdez, Didier, Sys, Gwen M.L., Tabone, Marie Dominique, Toulmonde, Maud, Valverde, Claudia, van de Sande, Michiel A.J., Wörtler, Klaus, Campbell-Hewson, Quentin, McCabe, Martin G., Nathrath, Michaela, Onderzoek Beeld, Green, Darrell, van Ewijk, Roelof, Tirtei, Elisa, Andreou, Dimosthenis, Baecklund, Fredrik, Baumhoer, Daniel, Bielack, Stefan S., Botchu, Rajesh, Boye, Kjetil, Brennan, Bernadette, Capra, Michael, Cottone, Lucia, Dirksen, Uta, Fagioli, Franca, Fernandez, Natalia, Flanagan, Adrienne M., Gambarotti, Marco, Gaspar, Nathalie, Gelderblom, Hans, Gerrand, Craig, Gomez-Mascard, Anne, Hardes, Jendrik, Hecker-Nolting, Stefanie, Kabickova, Edita, Kager, Leo, Kanerva, Jukka, Kester, Lennart A., Kuijjer, Marieke L., Laurence, Valérie, Lervat, Cyril, Marchais, Antonin, Marec-Berard, Perrine, Mendes, Cristina, Merks, Johannes H.M., Ory, Benjamin, Palmerini, Emanuela, Pantziarka, Pan, Papakonstantinou, Evgenia, Piperno-Neumann, Sophie, Raciborska, Anna, Roundhill, Elizabeth A., Rutkauskaite, Vilma, Safwat, Akmal, Scotlandi, Katia, Staals, Eric L., Strauss, Sandra J., Surdez, Didier, Sys, Gwen M.L., Tabone, Marie Dominique, Toulmonde, Maud, Valverde, Claudia, van de Sande, Michiel A.J., Wörtler, Klaus, Campbell-Hewson, Quentin, McCabe, Martin G., and Nathrath, Michaela

Published
2024

19. A comprehensive overview of liquid biopsy applications in pediatric solid tumors

Author

Onderzoek Beeld, Zorg en O&O, Cancer, Child Health, PMC Medisch specialisten, Genetica, Pathologie patiënten zorg, Pathologie Groep Van Diest, Janssen, Ferdinand W., Lak, Nathalie S.M., Janda, Claudia Y., Kester, Lennart A., Meister, Michael T., Merks, Johannes H.M., van den Heuvel-Eibrink, Marry M., van Noesel, Max M., Zsiros, Jozsef, Tytgat, Godelieve A.M., Looijenga, Leendert H.J., Onderzoek Beeld, Zorg en O&O, Cancer, Child Health, PMC Medisch specialisten, Genetica, Pathologie patiënten zorg, Pathologie Groep Van Diest, Janssen, Ferdinand W., Lak, Nathalie S.M., Janda, Claudia Y., Kester, Lennart A., Meister, Michael T., Merks, Johannes H.M., van den Heuvel-Eibrink, Marry M., van Noesel, Max M., Zsiros, Jozsef, Tytgat, Godelieve A.M., and Looijenga, Leendert H.J.

Published
2024

20. Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)

Author

Pathologie Moleculair, MS Gynaecologische Oncologie, Cancer, Aronson, S Lot, Walker, Cédric, Thijssen, Bram, van de Vijver, Koen K, Horlings, Hugo M, Sanders, Joyce, Alkemade, Maartje, Koole, Simone N, Lopez-Yurda, Marta, Lok, Christianne A R, Rottenberg, Sven, van Rheenen, Jacco, Sonke, Gabe S, van Driel, Willemien J, Kester, Lennart A, Hahn, Kerstin, OVHIPEC-1 Study Group, Pathologie Moleculair, MS Gynaecologische Oncologie, Cancer, Aronson, S Lot, Walker, Cédric, Thijssen, Bram, van de Vijver, Koen K, Horlings, Hugo M, Sanders, Joyce, Alkemade, Maartje, Koole, Simone N, Lopez-Yurda, Marta, Lok, Christianne A R, Rottenberg, Sven, van Rheenen, Jacco, Sonke, Gabe S, van Driel, Willemien J, Kester, Lennart A, Hahn, Kerstin, and OVHIPEC-1 Study Group

Published
2024

21. Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial

Author

Pathologie, Cancer, Urologie Opleiding, MS Medische Oncologie, Opdam, Mark, van Rossum, Annelot G.J., Hoogstraat, Marlous, Bounova, Gergana, Horlings, Hugo M., van Werkhoven, Erik, Mandjes, Ingrid A.M., van Leeuwen – Stok, A. Elise, Canisius, Sander, van Tinteren, Harm, Imholz, Alex L.T., Portielje, Johanneke E.A., Bos, Monique E.M.M., Bakker, Sandra, Wesseling, Jelle, Kester, Lennart, van Rheenen, Jacco, Rutgers, Emiel J., de Menezes, Renee X., Wessels, Lodewyk F.A., Kok, Marleen, Oosterkamp, Hendrika M., Linn, Sabine C., the MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG), Pathologie, Cancer, Urologie Opleiding, MS Medische Oncologie, Opdam, Mark, van Rossum, Annelot G.J., Hoogstraat, Marlous, Bounova, Gergana, Horlings, Hugo M., van Werkhoven, Erik, Mandjes, Ingrid A.M., van Leeuwen – Stok, A. Elise, Canisius, Sander, van Tinteren, Harm, Imholz, Alex L.T., Portielje, Johanneke E.A., Bos, Monique E.M.M., Bakker, Sandra, Wesseling, Jelle, Kester, Lennart, van Rheenen, Jacco, Rutgers, Emiel J., de Menezes, Renee X., Wessels, Lodewyk F.A., Kok, Marleen, Oosterkamp, Hendrika M., Linn, Sabine C., and the MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG)

Published
2024

22. Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial

Author

Opdam, Mark, van Rossum, Annelot G.J., Hoogstraat, Marlous, Bounova, Gergana, Horlings, Hugo M., van Werkhoven, Erik, Mandjes, Ingrid A.M., van Leeuwen – Stok, A. Elise, Canisius, Sander, van Tinteren, Harm, Imholz, Alex L.T., Portielje, Johanneke E.A., Bos, Monique E.M.M., Bakker, Sandra, Wesseling, Jelle, Kester, Lennart, van Rheenen, Jacco, de Menezes, Renee X., Wessels, Lodewyk F.A., Kok, Marleen, Oosterkamp, Hendrika M., Linn, Sabine C., Opdam, Mark, van Rossum, Annelot G.J., Hoogstraat, Marlous, Bounova, Gergana, Horlings, Hugo M., van Werkhoven, Erik, Mandjes, Ingrid A.M., van Leeuwen – Stok, A. Elise, Canisius, Sander, van Tinteren, Harm, Imholz, Alex L.T., Portielje, Johanneke E.A., Bos, Monique E.M.M., Bakker, Sandra, Wesseling, Jelle, Kester, Lennart, van Rheenen, Jacco, de Menezes, Renee X., Wessels, Lodewyk F.A., Kok, Marleen, Oosterkamp, Hendrika M., and Linn, Sabine C.

Abstract

The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can predict benefit from either docetaxel, doxorubicin, and cyclophosphamide (TAC) or dose-dense scheduled doxorubicin and cyclophosphamide (ddAC). Patients with a pT1-3, pN0-3 tumor were randomized 1:1 between ddAC and TAC. The primary endpoint was a gene profile-treatment interaction for recurrence-free survival (RFS). We observed 117 RFS events in 664 patients with a median follow-up of 7 years. Hallmark gene set analyses showed significant association between enrichment in immune-related gene expression and favorable outcome after TAC in hormone receptor-negative, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) (triple-negative breast cancer [TNBC]). We validated this association in TNBC patients treated with TAC on H&E slides; stromal tumor-infiltrating lymphocytes (sTILs) ≥20% was associated with longer RFS (hazard ratio 0.18, p = 0.01), while in patients treated with ddAC no difference in RFS was seen (hazard ratio 0.92, p = 0.86, pinteraction = 0.02).

Published
2024

23. Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

Author

Kemps, Paul G., Kester, Lennart, Scheijde-Vermeulen, Marijn A., van Noesel, Carel J.M., Verdijk, Robert M., Diepstra, Arjan, van Marion, Ariënne M.W., Dors, Natasja, van den Bos, Cor, Bruggink, Annette H., Hogendoorn, Pancras C.W., van Halteren, Astrid G.S., Kemps, Paul G., Kester, Lennart, Scheijde-Vermeulen, Marijn A., van Noesel, Carel J.M., Verdijk, Robert M., Diepstra, Arjan, van Marion, Ariënne M.W., Dors, Natasja, van den Bos, Cor, Bruggink, Annette H., Hogendoorn, Pancras C.W., and van Halteren, Astrid G.S.

Abstract

Aims: The discovery of somatic genetic alterations established many histiocytic disorders as haematologic neoplasms. We aimed to investigate the demographic characteristics and additional haematologic cancers of patients diagnosed with histiocytic disorders in The Netherlands. Methods and results: We retrieved data on histiocytosis patients from the Dutch Nationwide Pathology Databank (Palga). During 1993 to 2022, more than 4000 patients with a pathologist-assigned diagnosis of a histiocytic disorder were registered in Palga. Xanthogranulomas were the most common subtype, challenging the prevailing assumption that Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder. LCH and juvenile xanthogranuloma (JXG) had a peak incidence in the first years of life; males were overrepresented among all histiocytosis subgroups. 118 patients had a histiocytic disorder and an additional haematologic malignancy, including 107 (91%) adults at the time of histiocytosis diagnosis. In 16/118 patients, both entities had been analysed for the same genetic alteration(s). In 11 of these 16 patients, identical genetic alterations had been detected in both haematologic neoplasms. This included two patients with PAX5 p.P80R mutated B cell acute lymphoblastic leukaemia and secondary histiocytic sarcoma, further supporting that PAX5 alterations may predispose (precursor) B cells to differentiate into the myeloid lineage. All 4/11 patients with myeloid neoplasms as their additional haematologic malignancy had shared N/KRAS mutations. Conclusions: This population-based study highlights the frequency of xanthogranulomas. Furthermore, our data add to the growing evidence supporting clonal relationships between histiocytic/dendritic cell neoplasms and additional myeloid or lymphoid malignancies. Particularly adult histiocytosis patients should be carefully evaluated for the development of these associated haematologic cancers.

Published
2024

24. mRNA Expression Level of ALK in Neuroblastoma Is Associated with Histological Subtype, ALK Mutations and ALK Immunohistochemical Protein Expression.

Author

Bruinsma, Rixt S., Fiocco, Marta F., de Leng, Wendy W. J., Kester, Lennart A., Langenberg, Karin P. S., Tytgat, Godelieve A. M., van Noesel, Max M., Wijnen, Marc H. W. A., van der Steeg, Alida F. W., and de Krijger, Ronald R.

Subjects
NEUROBLASTOMA, PROTEIN expression, TRANSCRIPTOMES, SINGLE nucleotide polymorphisms, IMMUNOHISTOCHEMISTRY
Abstract

ALK is related to poor survival in neuroblastoma patients. We investigated the prognostic relevance of ALK mRNA expression and the relationship with ALK immunohistochemical expression, histological subtype and ALK aberrations. Whole transcriptome sequencing data were available from 54 patients. Overall survival (OS) and event-free survival (EFS) were estimated with Kaplan–Meier's methodology. ALK protein expression was analyzed by immunohistochemistry. ALK aberrations were detected using whole exome sequencing, single nucleotide polymorphism array, next generation sequencing and/or fluorescence in situ hybridization. OS was 74.8% and EFS was 60%. ALK mRNA expression was not associated with OS (HR 1.127, 95% CI (0.812–1.854), p = 0.331) and adjusted EFS (HR 1.134, 95% CI (0.783–1.644), p = 0.505), but was associated with histological subtype (OR 1.914, 95% CI (1.083–3.382), p = 0.025) and ALK protein expression (negative versus weak: OR 2.829, 95% CI (1.290–6.204), p = 0.009) (negative versus moderate/strong: OR 2.934, 95% CI (0.889–9.679), p = 0.077). ALK mutated tumors had significantly higher ALK mRNA expression than non-mutated tumors (p < 0.001). MYCN-amplified neuroblastomas have higher MYCN mRNA expression (p ≤ 0.001), but not ALK mRNA expression (p = 0.553). ALK mRNA expression is higher in ALK mutated neuroblastomas and is associated with poorer differentiation degree and higher protein expression. ALK mRNA expression is not significantly associated with OS and EFS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. NOTCH1 fusion genes in pediatric T-cell lymphoblastic lymphoma hallmark a common high-risk subgroup with blood TARC levels as possible diagnostic biomarker

Author

Kroeze, Emma, primary, Kleisman, Michelle M, additional, Kester, Lennart A, additional, Scheijde-Vermeulen, Marijn A, additional, Sonneveld, Edwin, additional, Buijs-Gladdines, Jessica GC, additional, Hagleitner, Melanie M, additional, Meyer-Wentrup, Friederike AG, additional, Veening, Margreet A, additional, Beishuizen, Auke, additional, Meijerink, Jules PP, additional, Loeffen, Jan LC, additional, and Kuiper, Roland P, additional

Published
2024
Full Text
View/download PDF

27. Molecular analysis of cancer genomes in children with Lynch syndrome: Exploring causal associations

Author

Weijers, Dilys D., primary, Hirsch, Steffen, additional, Bakhuizen, Jette J., additional, van Engelen, Nienke, additional, Kester, Lennart A., additional, Kranendonk, Mariëtte E. G., additional, Hiemcke‐Jiwa, Laura S., additional, de Vos‐Kerkhof, Evelien, additional, Loeffen, Jan L. C., additional, Autry, Robert J., additional, Pajtler, Kristian W., additional, Jäger, Natalie, additional, Jongmans, Marjolijn C. J., additional, and Kuiper, Roland P., additional

Published
2024
Full Text
View/download PDF

29. Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms.

Author

Kemps, Paul G, Kester, Lennart, Scheijde‐Vermeulen, Marijn A, van Noesel, Carel J M, Verdijk, Robert M, Diepstra, Arjan, van Marion, Ariënne M W, Dors, Natasja, van den Bos, Cor, Bruggink, Annette H, Hogendoorn, Pancras C W, and van Halteren, Astrid G S

Subjects
*DEMOGRAPHIC characteristics, *DENDRITIC cells, *LANGERHANS-cell histiocytosis, *CANCER patients, *TUMORS, *RETICULUM cell sarcoma
Abstract

Aims: The discovery of somatic genetic alterations established many histiocytic disorders as haematologic neoplasms. We aimed to investigate the demographic characteristics and additional haematologic cancers of patients diagnosed with histiocytic disorders in The Netherlands. Methods and results: We retrieved data on histiocytosis patients from the Dutch Nationwide Pathology Databank (Palga). During 1993 to 2022, more than 4000 patients with a pathologist‐assigned diagnosis of a histiocytic disorder were registered in Palga. Xanthogranulomas were the most common subtype, challenging the prevailing assumption that Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder. LCH and juvenile xanthogranuloma (JXG) had a peak incidence in the first years of life; males were overrepresented among all histiocytosis subgroups. 118 patients had a histiocytic disorder and an additional haematologic malignancy, including 107 (91%) adults at the time of histiocytosis diagnosis. In 16/118 patients, both entities had been analysed for the same genetic alteration(s). In 11 of these 16 patients, identical genetic alterations had been detected in both haematologic neoplasms. This included two patients with PAX5 p.P80R mutated B cell acute lymphoblastic leukaemia and secondary histiocytic sarcoma, further supporting that PAX5 alterations may predispose (precursor) B cells to differentiate into the myeloid lineage. All 4/11 patients with myeloid neoplasms as their additional haematologic malignancy had shared N/KRAS mutations. Conclusions: This population‐based study highlights the frequency of xanthogranulomas. Furthermore, our data add to the growing evidence supporting clonal relationships between histiocytic/dendritic cell neoplasms and additional myeloid or lymphoid malignancies. Particularly adult histiocytosis patients should be carefully evaluated for the development of these associated haematologic cancers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Author

Kroeze, Emma, primary, Iaccarino, Ingram, additional, Kleisman, Michelle M, additional, Mondal, Mayukh, additional, Beder, Thomas, additional, Khouja, Mouhamad, additional, Hoeppner, Marc P, additional, Scheijde-Vermeulen, Marijn, additional, Kester, Lennart A, additional, Brueggemann, Monika, additional, Baldus, Claudia D, additional, Cario, Gunnar, additional, Bladergroen, Reno S, additional, Garnier, Nathalie, additional, Attarbaschi, Andishe, additional, Verdu-Amoros, Jose Jaime, additional, Sutton, Rosemary, additional, MacIntyre, Elizabeth, additional, Scholten, Kenneth, additional, Padilla, Laura Arias, additional, Burkhardt, Birgit, additional, Beishuizen, Auke, additional, den Boer, Monique L, additional, Kuiper, Roland P, additional, Loeffen, Jan LC, additional, Boer, Judith M, additional, and Klapper, Wolfram, additional

Published
2023
Full Text
View/download PDF

31. INNV-36. ULTRA-FAST DEEP-LEARNED CNS TUMOR CLASSIFICATION USING NANOPORE-SEQUENCING DURING SURGERY

Author

Wesseling, Pieter, primary, Vermeulen, Carlo, additional, Pages-Gallego, Marc, additional, Kester, Lennart, additional, Kranendonk, Mariëtte, additional, Verburg, Niels, additional, Hamer, Philip de Witt, additional, Kooi, Evert-Jan, additional, Dankmeijer, Luuk, additional, van der Lugt, Jasper, additional, Van Baarsen, Kirsten, additional, Hoving, Eelco, additional, Tops, Bastiaan, additional, and De Ridder, Jeroen, additional

Published
2023
Full Text
View/download PDF

35. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity

Author

Kopper, Oded, de Witte, Chris J., Lõhmussaar, Kadi, Valle-Inclan, Jose Espejo, Hami, Nizar, Kester, Lennart, Balgobind, Anjali Vanita, Korving, Jeroen, Proost, Natalie, Begthel, Harry, van Wijk, Lise M., Revilla, Sonia Aristín, Theeuwsen, Rebecca, van de Ven, Marieke, van Roosmalen, Markus J., Ponsioen, Bas, Ho, Victor W. H., Neel, Benjamin G., Bosse, Tjalling, Gaarenstroom, Katja N., Vrieling, Harry, Vreeswijk, Maaike P. G., van Diest, Paul J., Witteveen, Petronella O., Jonges, Trudy, Bos, Johannes L., van Oudenaarden, Alexander, Zweemer, Ronald P., Snippert, Hugo J. G., Kloosterman, Wigard P., and Clevers, Hans

Published
2019
Full Text
View/download PDF

37. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’

Author

Langenberg, Karin P.S., Meister, Michael T., Bakhuizen, Jette J., Boer, Judith M., van Eijkelenburg, Natasha K.A., Hulleman, Esther, Ilan, Uri, Looze, Eleonora J., Dierselhuis, Miranda P., van der Lugt, Jasper, Breunis, Willemijn, Schild, Linda G., Ober, Kimberley, van Hooff, Sander R., Scheijde-Vermeulen, Marijn A., Hiemcke-Jiwa, Laura S., Flucke, Uta E., Kranendonk, Mariette E.G., Wesseling, Pieter, Sonneveld, Edwin, Punt, Simone, Boltjes, Arjan, van Dijk, Freerk, Verwiel, Eugene T.P., Volckmann, Richard, Hehir-Kwa, Jayne Y., Kester, Lennart A., Koudijs, Marco M.J., Waanders, Esme, Holstege, Frank C.P., Vormoor, H. Josef, Hoving, Eelco W., van Noesel, Max M., Pieters, Rob, Kool, Marcel, Stumpf, Miriam, Blattner-Johnson, Mirjam, Balasubramanian, Gnana P., Van Tilburg, Cornelis M., Jones, Barbara C., Jones, David T.W., Witt, Olaf, Pfister, Stefan M., Jongmans, Marjolijn C.J., Kuiper, Roland P., de Krijger, Ronald R., Wijnen, Marc H.W., den Boer, Monique L., Zwaan, C. Michel, Kemmeren, Patrick, Koster, Jan, Tops, Bastiaan B.J., Goemans, Bianca F., Molenaar, Jan J., Dep Scheikunde, Afd Pharmaceutics, Pharmaceutics, Dep Scheikunde, Afd Pharmaceutics, Pharmaceutics, Center of Experimental and Molecular Medicine, Oncogenomics, and CCA - Cancer Treatment and Quality of Life

Subjects
Cancer Research, Adolescent, Molecular biology, Precision medicine, High-Throughput Nucleotide Sequencing, Medical Oncology, Hereditary, Oncology, Neoplasms, Mutation, Exome Sequencing, Next-generation sequencing, Humans, Molecular targeted therapy, Prospective Studies, Child, Cancer
Abstract

iTHER is a Dutch prospective national precision oncology program aiming to define tumour molecular profiles in children and adolescents with primary very high-risk, relapsed, or refractory paediatric tumours. Between April 2017 and April 2021, 302 samples from 253 patients were included. Comprehensive molecular profiling including low-coverage whole genome sequencing (lcWGS), whole exome sequencing (WES), RNA sequencing (RNA-seq), Affymetrix, and/or 850k methylation profiling was successfully performed for 226 samples with at least 20% tumour content. Germline pathogenic variants were identified in 16% of patients (35/219), of which 22 variants were judged causative for a cancer predisposition syndrome. At least one somatic alteration was detected in 204 (90.3%), and 185 (81.9%) were considered druggable, with clinical priority very high (6.1%), high (21.3%), moderate (26.0%), intermediate (36.1%), and borderline (10.5%) priority. iTHER led to revision or refinement of diagnosis in 8 patients (3.5%). Temporal heterogeneity was observed in paired samples of 15 patients, indicating the value of sequential analyses. Of 137 patients with follow-up beyond twelve months, 21 molecularly matched treatments were applied in 19 patients (13.9%), with clinical benefit in few. Most relevant barriers to not applying targeted therapies included poor performance status, as well as limited access to drugs within clinical trial. iTHER demonstrates the feasibility of comprehensive molecular profiling across all ages, tumour types and stages in paediatric cancers, informing of diagnostic, prognostic, and targetable alterations as well as reportable germline variants. Therefore, WES and RNA-seq is nowadays standard clinical care at the Princess Máxima Center for all children with cancer, including patients at primary diagnosis. Improved access to innovative treatments within biology-driven combination trials is required to ultimately improve survival.

Published
2022
Full Text
View/download PDF

38. LGG-15. SINGLE-NUCLEUS AND BULK RNA SEQUENCING OF PEDIATRIC PILOCYTIC ASTROCYTOMAS REVEALS CNS LOCATION-ASSOCIATED TUMOR CELL AND MICROENVIRONMENTAL HETEROGENEITY

Author

Lammers, Julie A S, primary, Rozowsky, Jacob S, additional, Kranendonk, Mariëtte E G, additional, Schouten-van Meeteren, Antoinette Y N, additional, Meijer, Lisethe, additional, Calkoen, Friso G, additional, Hoving, Eelco W, additional, Wesseling, Pieter, additional, van der Lugt, Jasper, additional, and Kester, Lennart A, additional

Published
2023
Full Text
View/download PDF

40. Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS

Author

van Belzen, Ianthe A.E.M., Cai, Casey, van Tuil, Marc, Badloe, Shashi, Strengman, Eric, Janse, Alex, Verwiel, Eugène T.P., van der Leest, Douwe F.M., Kester, Lennart, Molenaar, Jan J., Meijerink, Jules, Drost, Jarno, Peng, Weng Chuan, Kerstens, Hindrik H.D., Tops, Bastiaan B.J., Holstege, Frank C.P., Kemmeren, Patrick, Hehir-Kwa, Jayne Y., van Belzen, Ianthe A.E.M., Cai, Casey, van Tuil, Marc, Badloe, Shashi, Strengman, Eric, Janse, Alex, Verwiel, Eugène T.P., van der Leest, Douwe F.M., Kester, Lennart, Molenaar, Jan J., Meijerink, Jules, Drost, Jarno, Peng, Weng Chuan, Kerstens, Hindrik H.D., Tops, Bastiaan B.J., Holstege, Frank C.P., Kemmeren, Patrick, and Hehir-Kwa, Jayne Y.

Abstract

Background: Gene fusions are important cancer drivers in pediatric cancer and their accurate detection is essential for diagnosis and treatment. Clinical decision-making requires high confidence and precision of detection. Recent developments show RNA sequencing (RNA-seq) is promising for genome-wide detection of fusion products but hindered by many false positives that require extensive manual curation and impede discovery of pathogenic fusions. Methods: We developed Fusion-sq to overcome existing disadvantages of detecting gene fusions. Fusion-sq integrates and “fuses” evidence from RNA-seq and whole genome sequencing (WGS) using intron–exon gene structure to identify tumor-specific protein coding gene fusions. Fusion-sq was then applied to the data generated from a pediatric pan-cancer cohort of 128 patients by WGS and RNA sequencing. Results: In a pediatric pan-cancer cohort of 128 patients, we identified 155 high confidence tumor-specific gene fusions and their underlying structural variants (SVs). This includes all clinically relevant fusions known to be present in this cohort (30 patients). Fusion-sq distinguishes healthy-occurring from tumor-specific fusions and resolves fusions in amplified regions and copy number unstable genomes. A high gene fusion burden is associated with copy number instability. We identified 27 potentially pathogenic fusions involving oncogenes or tumor-suppressor genes characterized by underlying SVs, in some cases leading to expression changes indicative of activating or disruptive effects. Conclusions: Our results indicate how clinically relevant and potentially pathogenic gene fusions can be identified and their functional effects investigated by combining WGS and RNA-seq. Integrating RNA fusion predictions with underlying SVs advances fusion detection beyond extensive manual filtering. Taken together, we developed a method for identifying candidate gene fusions that is suitable for precision oncology applications. Our method p

Published
2023

41. Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS

Author

Afd Pharmaceutics, Pharmaceutics, van Belzen, Ianthe A.E.M., Cai, Casey, van Tuil, Marc, Badloe, Shashi, Strengman, Eric, Janse, Alex, Verwiel, Eugène T.P., van der Leest, Douwe F.M., Kester, Lennart, Molenaar, Jan J., Meijerink, Jules, Drost, Jarno, Peng, Weng Chuan, Kerstens, Hindrik H.D., Tops, Bastiaan B.J., Holstege, Frank C.P., Kemmeren, Patrick, Hehir-Kwa, Jayne Y., Afd Pharmaceutics, Pharmaceutics, van Belzen, Ianthe A.E.M., Cai, Casey, van Tuil, Marc, Badloe, Shashi, Strengman, Eric, Janse, Alex, Verwiel, Eugène T.P., van der Leest, Douwe F.M., Kester, Lennart, Molenaar, Jan J., Meijerink, Jules, Drost, Jarno, Peng, Weng Chuan, Kerstens, Hindrik H.D., Tops, Bastiaan B.J., Holstege, Frank C.P., Kemmeren, Patrick, and Hehir-Kwa, Jayne Y.

Published
2023

42. Case Report:Immune dysregulation associated with long-lasting regression of a (pre)leukemic clone

Author

Koedijk, Joost B., van Beek, Thomas B., Vermeulen, Marijn A., Kester, Lennart A., Schweighart, Elizabeth K., Nierkens, Stefan, Belderbos, Mirjam E., Zwaan, C. Michel, Heitink-Pollé, Katja M.J., Heidenreich, Olaf, Koedijk, Joost B., van Beek, Thomas B., Vermeulen, Marijn A., Kester, Lennart A., Schweighart, Elizabeth K., Nierkens, Stefan, Belderbos, Mirjam E., Zwaan, C. Michel, Heitink-Pollé, Katja M.J., and Heidenreich, Olaf

Abstract

Regression of leukemia in the absence of disease-modifying therapy remains poorly understood, although immunological mechanisms are thought to play a role. Here, we present a unique case of a 17-year-old boy with immune dysregulation and long-lasting regression of a (pre)leukemic clone in the absence of disease-modifying therapy. Using molecular and immunological analyses, we identified bone marrow features associated with disease control and loss thereof. In addition, our case reveals that detection of certain fusion genes with hardly any blasts in the bone marrow may be indicative of an accompanying oncogenic fusion gene, with implications for disease surveillance- and management in future patients.

Published
2023

43. Asymptomatic lipofibroadenoma in a 17-year-old male:a case report and literature review of a rare entity

Author

den Bakker, Michael A., Vermeulen, Marijn A., van de Ven, Cornelis P., ter Horst, Simone A.J., Kester, Lennart, de Krijger, Ronald R., den Bakker, Michael A., Vermeulen, Marijn A., van de Ven, Cornelis P., ter Horst, Simone A.J., Kester, Lennart, and de Krijger, Ronald R.

Abstract

Background: The most common thymic tumours, thymomas, are derived from thymic epithelium and are generally low-grade neoplasm. Frankly malignant tumours, thymic carcinomas are rarer still. Exceedingly rare thymic tumours contain a mesenchymal tissue component such as fibrous connective tissue and/or mature fat. Lipofibroadenoma (LFA) is a very rare mixed epithelial-mesenchymal thymic tumour, included in the category of thymic epithelial tumors. LFA in addition to a mature adipocytic component, contains variable epithelial and mesenchymal tissue components. Owing to the presence of an epithelial component in LFA, this entity, in contrast to thymolipoma, is included in the World Health Organization (WHO) category of thymic epithelial neoplasm. Currently only 12 LFA cases have been described. The 12 previously reported cases all behaved in a benign fashion, although four cases were associated with a conventional type of thymoma. We here present a new, 13th, case of LFA. Case Description: The LFA was discovered incidentally in a previously healthy 17-year-old male after investigations for suspected pneumonia. On imaging a mass was discovered in the anterior mediastinum which was subsequently surgically removed. The resected tumour was extensively investigated, including the first instance of full molecular analysis of this rare entity and all available literature on LFA was sourced to provide a comprehensive overview. The histology of this LFA was similar to previously described cases. No gene mutations or rearrangements were identified. The patient made an uneventful recovery and after 13 months of follow-up remained well. Conclusions: An additional, 13th case of LFA is presented. Based on the available literature it appears that LFA may be considered a benign composite thymic tumour, although the combination of an additional conventional thymoma component may warrant closer follow-up.

Published
2023

44. Asymptomatic lipofibroadenoma in a 17-year-old male: a case report and literature review of a rare entity

Author

MS Radiologie, Cancer, Pathologie Pathologen staf, Pathologie Groep Van Diest, den Bakker, Michael A, Vermeulen, Marijn A, van de Ven, Cornelis P, Ter Horst, Simone A J, Kester, Lennart, de Krijger, Ronald R, MS Radiologie, Cancer, Pathologie Pathologen staf, Pathologie Groep Van Diest, den Bakker, Michael A, Vermeulen, Marijn A, van de Ven, Cornelis P, Ter Horst, Simone A J, Kester, Lennart, and de Krijger, Ronald R

Published
2023

45. Assessment of Cancer Predisposition Syndromes in a National Cohort of Children With a Neoplasm

Author

Genetica, Genetica Oper.Mang. Clinical Genetics, Cancer, Child Health, Speerpunt, Zorg en O&O, Genetica Klinische Genetica, Pathologie Moleculair, Genetica Sectie Genoomdiagnostiek, PMC Medisch specialisten, Onderzoek Beeld, Bakhuizen, Jette J., Hopman, Saskia M.J., Bosscha, Machteld I., Dommering, Charlotte J., van den Heuvel-Eibrink, Marry M., Hol, Janna A., Kester, Lennart A., Koudijs, Marco J., Langenberg, Karin P.S., Loeffen, Jan L.C., van der Lugt, Jasper, Moll, Annette C., van Noesel, Max M., Smetsers, Stephanie E., de Vos-Kerkhof, Evelien, Merks, Johannes H.M., Kuiper, Roland P., Jongmans, Marjolijn C.J., Genetica, Genetica Oper.Mang. Clinical Genetics, Cancer, Child Health, Speerpunt, Zorg en O&O, Genetica Klinische Genetica, Pathologie Moleculair, Genetica Sectie Genoomdiagnostiek, PMC Medisch specialisten, Onderzoek Beeld, Bakhuizen, Jette J., Hopman, Saskia M.J., Bosscha, Machteld I., Dommering, Charlotte J., van den Heuvel-Eibrink, Marry M., Hol, Janna A., Kester, Lennart A., Koudijs, Marco J., Langenberg, Karin P.S., Loeffen, Jan L.C., van der Lugt, Jasper, Moll, Annette C., van Noesel, Max M., Smetsers, Stephanie E., de Vos-Kerkhof, Evelien, Merks, Johannes H.M., Kuiper, Roland P., and Jongmans, Marjolijn C.J.

Published
2023

46. Case Report: Immune dysregulation associated with long-lasting regression of a (pre)leukemic clone

Author

Pathologie Moleculair, Cancer, CTI Research, Infection & Immunity, Arts-assistenten Kinderen, Speerpunt, MS Hematologie, Koedijk, Joost B, van Beek, Thomas B, Vermeulen, Marijn A, Kester, Lennart A, Schweighart, Elizabeth K, Nierkens, Stefan, Belderbos, Mirjam E, Zwaan, C Michel, Heitink-Pollé, Katja M J, Heidenreich, Olaf, Pathologie Moleculair, Cancer, CTI Research, Infection & Immunity, Arts-assistenten Kinderen, Speerpunt, MS Hematologie, Koedijk, Joost B, van Beek, Thomas B, Vermeulen, Marijn A, Kester, Lennart A, Schweighart, Elizabeth K, Nierkens, Stefan, Belderbos, Mirjam E, Zwaan, C Michel, Heitink-Pollé, Katja M J, and Heidenreich, Olaf

Published
2023

47. Case Report: Immune dysregulation associated with long-lasting regression of a (pre) leukemic clone.

Author

Koedijk, Joost B., van Beek, Thomas B., Vermeulen, Marijn A., Kester, Lennart A., Schweighart, Elizabeth K., Nierkens, Stefan, Belderbos, Mirjam E., Zwaan, C. Michel, Heitink-Pollé, Katja M. J., and Heidenreich, Olaf

Subjects
PRELEUKEMIA, GENE fusion, BLAST injuries, BONE marrow, DISEASE management, ACUTE myeloid leukemia, PREVENTIVE medicine
Abstract

Regression of leukemia in the absence of disease-modifying therapy remains poorly understood, although immunological mechanisms are thought to play a role. Here, we present a unique case of a 17-year-old boy with immune dysregulation and long-lasting regression of a (pre)leukemic clone in the absence of disease-modifying therapy. Using molecular and immunological analyses, we identified bone marrow features associated with disease control and loss thereof. In addition, our case reveals that detection of certain fusion genes with hardly any blasts in the bone marrow may be indicative of an accompanying oncogenic fusion gene, with implications for disease surveillance- and management in future patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Supplementary Figure from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

Author

Kester, Lennart, primary, Seinstra, Danielle, primary, van Rossum, Annelot G.J., primary, Vennin, Claire, primary, Hoogstraat, Marlous, primary, van der Velden, Daphne, primary, Opdam, Mark, primary, van Werkhoven, Erik, primary, Hahn, Kerstin, primary, Nederlof, Iris, primary, Lips, Ester H., primary, Mandjes, Ingrid A.M., primary, van Leeuwen-Stok, A. Elise, primary, Canisius, Sander, primary, van Tinteren, Harm, primary, Imholz, Alex L.T., primary, Portielje, Johanneke E.A., primary, Bos, Monique E.M.M., primary, Bakker, Sandra D., primary, Rutgers, Emiel J., primary, Horlings, Hugo M., primary, Wesseling, Jelle, primary, Voest, Emile E., primary, Wessels, Lodewyk F.A., primary, Kok, Marleen, primary, Oosterkamp, Hendrika M., primary, van Oudenaarden, Alexander, primary, Linn, Sabine C., primary, and van Rheenen, Jacco, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Table from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

Author

Kester, Lennart, primary, Seinstra, Danielle, primary, van Rossum, Annelot G.J., primary, Vennin, Claire, primary, Hoogstraat, Marlous, primary, van der Velden, Daphne, primary, Opdam, Mark, primary, van Werkhoven, Erik, primary, Hahn, Kerstin, primary, Nederlof, Iris, primary, Lips, Ester H., primary, Mandjes, Ingrid A.M., primary, van Leeuwen-Stok, A. Elise, primary, Canisius, Sander, primary, van Tinteren, Harm, primary, Imholz, Alex L.T., primary, Portielje, Johanneke E.A., primary, Bos, Monique E.M.M., primary, Bakker, Sandra D., primary, Rutgers, Emiel J., primary, Horlings, Hugo M., primary, Wesseling, Jelle, primary, Voest, Emile E., primary, Wessels, Lodewyk F.A., primary, Kok, Marleen, primary, Oosterkamp, Hendrika M., primary, van Oudenaarden, Alexander, primary, Linn, Sabine C., primary, and van Rheenen, Jacco, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

Author

Kester, Lennart, primary, Seinstra, Danielle, primary, van Rossum, Annelot G.J., primary, Vennin, Claire, primary, Hoogstraat, Marlous, primary, van der Velden, Daphne, primary, Opdam, Mark, primary, van Werkhoven, Erik, primary, Hahn, Kerstin, primary, Nederlof, Iris, primary, Lips, Ester H., primary, Mandjes, Ingrid A.M., primary, van Leeuwen-Stok, A. Elise, primary, Canisius, Sander, primary, van Tinteren, Harm, primary, Imholz, Alex L.T., primary, Portielje, Johanneke E.A., primary, Bos, Monique E.M.M., primary, Bakker, Sandra D., primary, Rutgers, Emiel J., primary, Horlings, Hugo M., primary, Wesseling, Jelle, primary, Voest, Emile E., primary, Wessels, Lodewyk F.A., primary, Kok, Marleen, primary, Oosterkamp, Hendrika M., primary, van Oudenaarden, Alexander, primary, Linn, Sabine C., primary, and van Rheenen, Jacco, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results